USPTO serial 79363592
PHARMACOSMOS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 2, 2024
- Examiner
- MESSICK, TABITHA LEE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PHARMACOSMOS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shannon Marie McKeon
Shannon Marie McKeon Dykema Gossett PLLC1301 K Str., N.W., Suite 1100Washington, DC 20005United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Glucose for industrial purposes; glucose derivatives for industrial purposes; glucose oligo- and polysaccharides for industrial purposes; dextran being glucose for industrial purposes; dextran derivatives being glucose for industrial purposes; industrial chemicals, namely, excipients, cryoprotectants, lyoprotectants and media for use in storing, freezing, growing and thawing of human, plant or animal cells or tissue for non-medical purposes; industrial chemicals, namely, excipients, cryoprotectants, lyoprotectants and media in the nature of carbohydrates or carbohydrate derivatives, glucose, glucose derivatives, glucose oligo- and polysaccharides, dextran, and/or dextran derivatives, oligosaccharides, polysaccharides, derivatives of oligosaccharides and polysaccharides, glucose oligosaccharides, glucose polysaccharides, derivatives of glucose oligosaccharides and glucose polysaccharides, nanomolecules, iron nano molecules, polynuclear iron carbohydrate complexes, iron oligosaccharides complexes, iron polysaccharide complexes, iron chelators, written transfection agents, in solid, liquid or gaseous state for use in storing, freezing, growing and thawing of human, plant or animal cells or tissue for non-medical purposes; industrial chemicals, namely, excipients, cryoprotectants, lyoprotectants and media in the nature of non-carbohydrates in solid, liquid or gaseous state for use in storing, freezing, growing and thawing of human, plant or animal cells or tissue for non-medical purposes; chemicals for use as excipients, cryoprotectants, lyoprotectants and media in the manufacture of pharmaceuticals; biological tissue cultures other than for medical or veterinary purposes; chemicals for use in the manufacture of cosmetics; chemicals for use in the manufacture of food supplements; industrial chemicals, namely, carbohydrates or carbohydrate derivatives, glucose, glucose derivatives, glucose oligo- and/or polysaccharides, dextran, and dextran derivatives for use in chromatography, separation systems, molecular weight measurements, lyophilization, cell media, transfection, and industrial applications; nanopowders for industrial purposes; industrial chemicals, namely, excipients, cryoprotectants, lyoprotectants and media for use in storing, growing, freezing and thawing of human, plant or animal cells or tissue for research purposes | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload in humans; veterinary preparations for the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload in animals; dietary supplements for human beings and animals; dietetic food and substances, namely, beverages adapted for medical and veterinary purposes; diagnostic preparations for medical and veterinary purposes; molecular weight testing reagents for diagnostic purposes; medical, pharmaceutical and veterinary preparations for parenteral administration, in particular oral, intravenous, intramuscular and subcutaneous, for the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload; iron preparations for pharmaceutical and veterinary use in the nature of dietary supplements consisting primarily of iron; iron preparations as food supplements; glucose for medical purposes; diagnostic agents, preparations and substances for medical purposes, namely, excipients, cryoprotectants, lyoprotectants and media for use in storing, growing, freezing and thawing of human, plant or animal cells or tissue for medical or veterinary purposes, not for manufacturing; diagnostic agents, preparations and substances for medical purposes, namely, excipients, cryoprotectants, lyoprotectants and media in the nature of carbohydrates in solid, liquid or gaseous state for use in storing, freezing, growing and thawing of human, plant or animal cells or tissue for medical or veterinary purposes not for manufacturing; diagnostic agents, preparations and substances for medical purposes, namely, excipients, cryoprotectants, lyoprotectants and media in the nature of non-carbohydrates in solid, liquid or gaseous state for use in storing, freezing, growing and/or thawing of human, plant or animal cells or tissue for medical or veterinary purposes not for manufacturing; biological tissue cultures for medical and veterinary purposes; chemical preparations for medical and pharmaceutical purposes, namely, for the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload; chemical preparations for veterinary purposes, namely, for the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload; chemical reagents for medical or veterinary purposes | ACTIVE | — |
| 042 | Scientific research for medical, veterinary and chemical purposes; scientific research in the nature of conducting clinical trials in the field of treatment and/or prevention of iron deficiency and/or anaemia or of iron overload; scientific research for medical and chemical purposes in the field of storing, freezing, growing and/or thawing biological material, cells, cancer cells and stem cells; providing medical and scientific research information relating to pharmaceuticals and clinical trials; molecular weight testing services for scientific research purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Pharmacosmos Holding A/S
- Other trademarks owned by Pharmacosmos Holding A/S
- Other trademarks owned by Pharmacosmos Holding A/S
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PHARMACOSMOS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 23, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Apr 6, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 6, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 11, 2025 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Nov 8, 2024 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Oct 2, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 2, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 2, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 16, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 16, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 16, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 27, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 27, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 27, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 8, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 13, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 13, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 5, 2024 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Dec 17, 2023 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Sep 13, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 19, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 19, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 26, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 25, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 18, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 17, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 13, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 3, 2023 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Feb 23, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |